Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation
Clinical trials sponsored by Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New TB vaccine aims to prevent active lung disease in adults Results expected Dec 2026 (estimated)
- Scientists hunt Tick-Borne germs to unlock disease patterns Results expected Dec 2026 (estimated)
-
New antibody drug aims to tackle COVID-19 early
Disease control Not yet recruitingThis early-stage trial tests a new drug called B10-FC, which is a lab-made antibody designed to fight the SARS-CoV-2 virus. The study will first give the drug to 25 healthy volunteers in increasing doses to check safety, then to 10 COVID-19 patients. The main goal is to see if th…
Phase 1 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: Disease control
Last updated Jun 26, 2026 13:33 UTC
-
New russian drug fluorothiazinone enters first human safety tests
Knowledge-focused Not yet recruitingThis early-stage trial will test the safety of a new drug called fluorothiazinone in 70 healthy adults aged 18 to 45. Participants will receive either a single dose or a short course of the drug or a placebo. The main goal is to check for side effects and how the drug moves throu…
Phase 1 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC